Skip to main content
SOLARA ACTIVE PHARMA SCIENCES LIMITED logo

SOLARA ACTIVE PHARMA SCIENCES LIMITED — Investor Relations & Filings

Ticker · SOLARA ISIN · INE624Z01016 LEI · 3358008SUKH3YE2F7F81 BSE.NS Manufacturing
Open in API
Filings indexed 664 across all filing types
Latest filing 2026-05-15 Earnings Release
Country IN India
Listing BSE.NS SOLARA

About SOLARA ACTIVE PHARMA SCIENCES LIMITED

https://www.solara.co.in/

Solara Active Pharma Sciences Limited is a customer-centric organization specializing in the development and manufacturing of active pharmaceutical ingredients (APIs). The company offers a diverse portfolio of high-quality products across therapeutic categories such as pain management, central nervous system, and anti-infectives. It operates several manufacturing sites and research centers that comply with global regulatory standards, including the USFDA and EUGMP. Beyond its commercial API catalog, the company provides comprehensive contract development and manufacturing organization (CDMO) services, assisting partners from the initial research phase to large-scale production. Known for its significant production capacity in key molecules like Ibuprofen, the company focuses on delivering complex and niche APIs to global markets through advanced technical expertise and a commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Solara Active Pharma Sciences Limited has informed the Exchange regarding the Press release dated May 15, 2026, titled Strong Q4''26 Results and a solid finish to the fiscal year
Earnings Release Classification · 87% confidence The document is a press release pursuant to SEBI Listing Regulations announcing the company’s Q4 and full-year FY26 financial results. It includes the earnings presentation slides and key financial highlights for the quarter and year ended March 31, 2026. This matches the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). FY 2026
2026-05-15 English
Press Release
Earnings Release Classification · 98% confidence The document is a press release filed under SEBI Listing Regulations to announce Q4 and FY26 financial results, including key highlights, revenue/EBITDA metrics, and a link to an accompanying earnings presentation. It contains summarized financial performance metrics rather than full statutory financial statements, and it serves as the initial announcement of quarterly results. This aligns with the definition of an Earnings Release (ER). FY 2026
2026-05-15 English
Solara Active Pharma Sciences Limited has informed the Exchange regarding interalia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended ....
Audit Report / Information Classification · 79% confidence The document is a formal SEBI (Listing Obligations and Disclosure Requirements) submission containing the Board’s approval of the audited standalone and consolidated financial results for the year ended March 31, 2026, the unaudited quarterly results for the quarter ended March 31, 2026, plus the independent auditor’s report with unmodified opinion. It is not a full annual report (10-K), not merely an earnings highlight (ER), nor an announcement of availability (RPA). Instead, it is the standalone audit report and associated audited financial statements, which fits the definition of an Audit Report / Information filing.
2026-05-15 English
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended ....
Audit Report / Information Classification · 85% confidence The document is a combined Board meeting outcome announcement under SEBI Listing Regulations, providing the Audited Annual Financial Results (Standalone & Consolidated) for year and quarter ended March 31, 2026, accompanied by the Independent Auditor’s Report with unmodified opinion. This is not a full Annual Report (10-K), nor a simple publication notice (RPA), nor merely highlights (ER). It is fundamentally the audit report on the financial results, which matches the definition of an Audit Report / Information (AR).
2026-05-15 English
Outcome of Board Meeting
Audit Report / Information Classification · 92% confidence The document contains the Independent Auditor’s Report on the audit of the annual consolidated financial results and review of quarterly consolidated financial results under SEBI Listing Regulations. It goes beyond a simple announcement and includes the auditors’ opinion, basis for opinion, and detailed report structure. This fits the definition of a standalone Audit Report / Information, rather than an Annual Report, earnings release, or mere publication announcement.
2026-05-15 English
Revised Intimation of Schedule of Investors/Analysts call to be held on Friday, May 15, 2026, 15.00 IST to discuss the Company''s audited financial results for the quarter and year ended ....
Regulatory Filings Classification · 13% confidence The document is a stock exchange intimation under SEBI Listing Regulations notifying a change in a panel member for an upcoming analysts/investors conference call. It does not contain financial results or presentation materials itself, nor is it the transcript; it is a regulatory compliance announcement. There is no detailed financial data or report attached. It falls under general regulatory filings as a compliance notice (fallback category).
2026-05-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.